Nuveen LLC Purchases Shares of 301,571 Maravai LifeSciences Holdings, Inc. $MRVI

Nuveen LLC purchased a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 301,571 shares of the company’s stock, valued at approximately $666,000. Nuveen LLC owned approximately 0.12% of Maravai LifeSciences as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in MRVI. Deutsche Bank AG boosted its stake in shares of Maravai LifeSciences by 67.6% in the 1st quarter. Deutsche Bank AG now owns 2,072,239 shares of the company’s stock valued at $4,580,000 after purchasing an additional 835,600 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Maravai LifeSciences by 2,005.9% in the 1st quarter. SG Americas Securities LLC now owns 695,907 shares of the company’s stock valued at $1,538,000 after purchasing an additional 662,861 shares in the last quarter. CenterBook Partners LP boosted its stake in shares of Maravai LifeSciences by 67.2% in the 1st quarter. CenterBook Partners LP now owns 1,357,600 shares of the company’s stock valued at $3,000,000 after purchasing an additional 545,674 shares in the last quarter. Monaco Asset Management SAM boosted its stake in shares of Maravai LifeSciences by 186.9% in the 1st quarter. Monaco Asset Management SAM now owns 835,865 shares of the company’s stock valued at $1,847,000 after purchasing an additional 544,501 shares in the last quarter. Finally, Royce & Associates LP boosted its stake in shares of Maravai LifeSciences by 38.5% in the 1st quarter. Royce & Associates LP now owns 1,328,444 shares of the company’s stock valued at $2,936,000 after purchasing an additional 369,559 shares in the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on MRVI shares. Royal Bank Of Canada decreased their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, August 12th. Craig Hallum decreased their price objective on Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. Finally, Robert W. Baird decreased their price objective on Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating on the stock in a report on Tuesday, May 13th. Three research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $5.22.

Maravai LifeSciences Stock Down 0.4%

Shares of NASDAQ:MRVI opened at $2.36 on Thursday. Maravai LifeSciences Holdings, Inc. has a 1 year low of $1.66 and a 1 year high of $9.60. The company has a market cap of $602.65 million, a PE ratio of -1.74 and a beta of 0.29. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49. The stock’s 50-day moving average is $2.49 and its 200 day moving average is $2.40.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.